Showing results (61-70 of 75) with videos related to
Sort By:
Pageof 8
The Australian and New Zealand Journal of Psychiatry|February 26, 2010
Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approachesStanley V Catts, Brian I O'Toole, Vaughan J Carr, et al.Journal of Medical Genetics|February 10, 2023
Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen StudyJane M Tiller, Nicole E Cousens, Rajneesh Kaur, et al.Journal of Clinical Immunology|October 17, 2021
Hyper-IgE Syndrome due to an Elusive Novel Intronic Homozygous Variant in DOCK8Stuart G Tangye, Paul E Gray, Bethany A Pillay, et al.BMJ Open|June 26, 2021
Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paperNicole E Cousens, Jane Tiller, Bettina Meiser, et al.Brain Sciences|January 26, 2024
Neuropathological Applications of Microscopy with Ultraviolet Surface Excitation (MUSE): A Concordance Study of Human Primary and Metastatic Brain TumorsMirna Lechpammer, Austin Todd, Vivian Tang, et al.European Journal of Human Genetics : EJHG|January 13, 2021
Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencingAmali C Mallawaarachchi, Ben Lundie, Yvonne Hort, et al.Cell Chemical Biology|August 13, 2025
Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancersWadie D Mahauad-Fernandez, Yu Chi Yang, Ian Lai, et al.Nature Chemical Biology|June 25, 2021
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growthBianca J Lee, Jacob A Boyer, G Leslie Burnett, et al.The Journal of Clinical Investigation|December 8, 2020
Somatic reversion of pathogenic DOCK8 variants alters lymphocyte differentiation and function to effectively cure DOCK8 deficiencyBethany A Pillay, Mathieu Fusaro, Paul E Gray, et al.Journal of Medicinal Chemistry|December 19, 2022
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated TumorsG Leslie Burnett, Yu C Yang, James B Aggen, et al.Pageof 8